Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Betting on Safety: The IoM Report's Impact on Wall Street

This article was originally published in RPM Report

Executive Summary

The Institute of Medicine is recommending big changes in how FDA deals with drug safety issues. Is it possible that will be good news on Wall Street? Drug safety expert and managing director of investment company Symphony Capital, Alastair Wood, weighs in.

You may also be interested in...



IoM's Sheila Burke on the Drug Safety Climate

The chair of the Institute of Medicine drug safety committee, Sheila Burke, agreed to an interview with The RPM Report on about issues related to the Food & Drug Administration's approval process and the debate on Capitol Hill over proposed legislation. Here are excerpts of the conversation.

Everything but the Kitchen Sink: IoM Drug Safety Report Gives FDA Options

The Institute of Medicine's drug safety committee came down hard on FDA's efforts to make sure drugs they approve are safe and effective. But FDA dodged a bullet based on what isn't in the report.

Moving Beyond Aduhelm: Cell/Gene Therapy May Be ‘Poster Child’ For What Comes Next

Former FDA principal deputy commissioner Amy Abernethy says cell and gene therapy is an area primed for improved ‘parallel conversation’ between FDA and CMS on data requirements.

Topics

Related Companies

UsernamePublicRestriction

Register

PS079972

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel